Susceptibility | All isolates | Sampled clinical cases | |||
---|---|---|---|---|---|
Total | CABSI | HABSI | P value a | ||
Methicillin (MRSA) | 40/108 (37%) | 12/38 (31.6%) | 12/31 (38.7%) | 0/7 (0%) | 0.074 |
Erythromycin | 39/72 (54.2%) | 11/23 (47.8%) | 10/18 (55.6%) | 1/5 (20%) | 0.317 |
Clindamycin | 56/109 (51.4%) | 21/40 (52.5%) | 18/23 (54.5%) | 3/7 (42.9%) | 0.689 |
Chloramphenicol | 35/105 (33.3%) | 14/38 (36.8%) | 11/31 (35.5%) | 3/7 (42.9%) | 1 |
Gentamicin | 18/76 (23.7%) | 9/26 (34.6%) | 7/21 (33.3%) | 2/5 (40%) | 1 |
Ciprofloxacin | 19/99 (19.2%) | 7/33 (21.2%) | 6/28 (21.4%) | 1/5(20%) | 1 |
Levofloxacin | 18/103 (17.5%) | 9/40 (22.5%) | 6/13 (18.2%) | 3/7 (42.9%) | 0.316 |
Co-trimoxazole | 8/62 (12.9%) | 5/28(17.9%) | 4/21 (19%) | 1/7 (14.3%) | 1 |
Rifampicin | 10/95 (10.5%) | 6/33 (18.2%) | 5/27 (18.5%) | 1/6 (16.7%) | 1 |
Vancomycinb | 0/63 (0%) | - | - | - | - |